Fulcrum Therapeutics Inc. (FULC) Tops Q3 EPS by 8c; Cash and Cash Equivalents of $240.3M

Fulcrum Therapeutics Inc. (NASDAQ: FULC) reported Q3 EPS of ($0.57), $0.08 better than the analyst estimate of ($0.65). Revenue for the quarter came in at $4.9 million versus the consensus estimate of $2.25 million.

For earnings history and earnings-related data on Fulcrum Therapeutics Inc. (FULC) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• AeroVironment restates quarterly financials, citing $89M goodwill error
• Hermès can regain momentum despite China weakness, Jefferies says